Ylä-Herttuala S - Search Results

1

Finnish Society of Gene and Cell Therapy: A Visionary and Creative Player in the Field.

Tirronen A, Ylä-Herttuala S. Tirronen A, et al. Hum Gene Ther. 2021 Oct;32(19-20):986. doi: 10.1089/hum.2021.29176.ati. Hum Gene Ther. 2021. PMID: 34662230 No abstract available.

2

Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses.

Sandmair AM, Loimas S, Puranen P, Immonen A, Kossila M, Puranen M, Hurskainen H, Tyynelä K, Turunen M, Vanninen R, Lehtolainen P, Paljärvi L, Johansson R, Vapalahti M, Ylä-Herttuala S. Sandmair AM, et al. Hum Gene Ther. 2000 Nov 1;11(16):2197-205. doi: 10.1089/104303400750035726. Hum Gene Ther. 2000. PMID: 11084677 Clinical Trial.

3

HSV-tk gene therapy for human renal cell carcinoma in nude mice.

Pulkkanen KJ, Parkkinen JJ, Laukkanen JM, Kettunen MI, Tyynela K, Kauppinen RA, Ala-Opas MY, Yla-Herttuala S. Pulkkanen KJ, et al. Cancer Gene Ther. 2001 Jul;8(7):529-36. doi: 10.1038/sj.cgt.7700342. Cancer Gene Ther. 2001. PMID: 11498775

4

Baculoviruses exhibit restricted cell type specificity in rat brain: a comparison of baculovirus- and adenovirus-mediated intracerebral gene transfer in vivo.

Lehtolainen P, Tyynelä K, Kannasto J, Airenne KJ, Ylä-Herttuala S. Lehtolainen P, et al. Gene Ther. 2002 Dec;9(24):1693-9. doi: 10.1038/sj.gt.3301854. Gene Ther. 2002. PMID: 12457283

5

Extracellular superoxide dismutase with vaccinia virus anti-inflammatory protein 35K or tissue inhibitor of metalloproteinase-1: Combination gene therapy in the treatment of vein graft stenosis in rabbits.

Turunen P, Puhakka HL, Heikura T, Romppanen E, Inkala M, Leppänen O, Ylä-Herttuala S. Turunen P, et al. Hum Gene Ther. 2006 Apr;17(4):405-14. doi: 10.1089/hum.2006.17.405. Hum Gene Ther. 2006. PMID: 16610928

6

Oxidative stress-inducible lentiviral vectors for gene therapy.

Hurttila H, Koponen JK, Kansanen E, Jyrkkänen HK, Kivelä A, Kylätie R, Ylä-Herttuala S, Levonen AL. Hurttila H, et al. Gene Ther. 2008 Sep;15(18):1271-9. doi: 10.1038/gt.2008.75. Epub 2008 May 1. Gene Ther. 2008. PMID: 18449215

7

Production of HIV-1 integrase fusion protein-carrying lentiviral vectors for gene therapy and protein transduction.

Schenkwein D, Turkki V, Kärkkäinen HR, Airenne K, Ylä-Herttuala S. Schenkwein D, et al. Hum Gene Ther. 2010 May;21(5):589-602. doi: 10.1089/hum.2009.051. Hum Gene Ther. 2010. PMID: 20039782

8

Future prospects and challenges of antiangiogenic cancer gene therapy.

Samaranayake H, Määttä AM, Pikkarainen J, Ylä-Herttuala S. Samaranayake H, et al. Hum Gene Ther. 2010 Apr;21(4):381-96. doi: 10.1089/hum.2010.017. Hum Gene Ther. 2010. PMID: 20163246 Review.

9

Progress and prospects: hurdles to cardiovascular gene therapy clinical trials.

Hedman M, Hartikainen J, Ylä-Herttuala S. Hedman M, et al. Gene Ther. 2011 Aug;18(8):743-9. doi: 10.1038/gt.2011.43. Epub 2011 Apr 14. Gene Ther. 2011. PMID: 21490683 Review.

10

History of gene therapy.

Wirth T, Parker N, Ylä-Herttuala S. Wirth T, et al. Gene. 2013 Aug 10;525(2):162-9. doi: 10.1016/j.gene.2013.03.137. Epub 2013 Apr 23. Gene. 2013. PMID: 23618815 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

757 results

Search Page